FDA Approves Second Gene Therapy for Hemophilia B FDA Approves Second Gene Therapy for Hemophilia B

Pfizer reported a list price of $3.5 million for its new gene therapy, Beqvez, for adults with this rare bleeding disorder.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Internal Medicine News Alert Source Type: news